Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Osseous manifestations of sarcoidosis are uncommon. We aimed to characterize clinical presentation, distribution of lesions, treatment, and outcomes of bone sarcoidosis.
A French retrospective multicenter study of patients with biopsy-proven sarcoidosis and osseous manifestations was analyzed. Inclusion criteria for sarcoidosis with bone involvement were 1) a biopsy-proven granuloma without caseous necrosis and either 2) bone clinical manifestations or 3) abnormal bone imaging. Musculo-squeletal involvement with isolated joint or muscular manifestations were excluded. Sarcoidosis patients with bone involvement (patients) were compared to 264 age- and sex-matched patients with a biopsy-proven sarcoidosis and no bone manifestations (controls).
In bone sarcoidosis group (n=88), the median age [IQR] at sarcoidosis diagnosis was 41 [34-51] years, and 44 (50%) patients were women. Forty two out of 88 (48%) patients had bone related symptoms, involving mainly axial (69%) and/or appendicular (58%) skeleton. On imaging, spine was the most commonly affected bone (52%), followed by pelvis (42%), hands (22%) and femur (19%). Bone biopsy showed granuloma without caseous necrosis in 17/25 (68%) patients. Compared to controls, bone sarcoidosis patients had higher rates of mediastinal (93% vs 47%, P < 0.0001) and extra-thoracic lymph node (66% vs 21%, P < 0.0001), and pulmonary (90% vs 65%, P < 0.0001) and cutaneous involvement (44% vs 23%, P < 0.0001). Gastro-intestinal involvement was less frequent in bone sarcoidosis group (1% vs 17%, P < 0.0001). Hypercalcemia was observed in 8.5% of patients compared to 2% of controls (P=0.014). Seven patients did not receive specific treatment for bone sarcoidosis. Glucocorticoid was used in 63/81 (78%) patients, alone in 44 patients, and associated with methotrexate in 13 patients or hydroxychloroquine in 6 patients. Rates of clinical and/or radiological response of bone sarcoidosis were 23/44 (52%), 9/13 (70%) and 4/6 (67%), respectively.
In patients with bone sarcoidosis, spine and pelvis were the most commonly affected bones. Patients with bone sarcoidosis compared to sarcoidosis patients with no bone involvement have higher rates of thoracic and extra-thoracic lymph node, pulmonary, cutaneous involvement and hypercalcemia. Most patients with bone sarcoidosis had a good response to glucocorticoids used alone or in association with methotrexate or hydroxychloroquine.
To cite this abstract in AMA style:Ben hassine I, Rein C, Comarmond C, Chapelon-Abric C, Saidenberg N, Meunier B, Schleinitz N, Chanson N, Scherlinger M, Richez C, Hirschi S, Groh M, Devilliers H, Saadoun D, Arnaud L, Cacoub P. BONE Sarcoidosis: A French Case Control Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/bone-sarcoidosis-a-french-case-control-study/. Accessed May 24, 2019.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/bone-sarcoidosis-a-french-case-control-study/